The US Food and Drug Administration gives the green light to the use of bebtelovimab for the treatment of Omicron strain

The US Food and Drug Administration gives the green light to the use of bebtelovimab for the treatment of Omicron strain


On Friday, the US Food and Drug Administration issued an emergency use authorization for a new treatment to treat the mutated Omicron strain of the Corona virus, US media reported.


The new treatment, called bebtelovimab, is intended to treat mild to moderate infections in adults and children (12 years and older and weigh at least 40 kg).


Treatment is also intended for those at high risk of severe infection who do not have access to alternative treatment options approved or authorized by the US Food and Drug Administration or are clinically inappropriate.


bebtelovimab is not approved for patients who are hospitalized or need oxygen therapy for an infection.


It is reported that, there is a significant increase in cases of Corona virus infection caused by the highly transmissible Omicron variant, so the Japanese Ministry of Health granted rapid approval for Corona pills that are taken orally from Pfizer to treat mild infections, and it is called Paxlovid, which is a mixture of antiviral drugs. Nirmatrelvir and ritonavir, the second oral drug the country has approved for use in patients with mild symptoms, in December Japan approved molnupiravir, the oral drug developed by US drug maker Merck & Co.


Pfizer's Paxlovid contains nirmatilvir and ritonavir tablets. While nirmatilvir prevents the replication of the Corona virus by inhibiting the viral protein, ritonavir slows down the breakdown of nirmatilvir so that it stays in the body for a longer time at higher concentrations.


Paxlovid is given as three tablets, two nirmatrelvir tablets and one ritonavir tablet taken together orally twice daily for five days, for a total of 30 tablets, but it is not recommended to use the medicine for more than five consecutive days.


The US Food and Drug Administration authorized the use of Paxlovid to treat mild to moderate COVID-19 in adults and children (12 years and over) on December 22, 2021, and stated that Paxlovid should be started as soon as possible after COVID-19 is diagnosed and within 5 days of symptoms appearing.



***Possible side effects of Paxilovide

The US Food and Drug Administration has warned that Paxlovid should not be used for pre-exposure or post-exposure prophylaxis, and it is not authorized to start treatment for those who need hospitalization due to severe or critical corona, and said that Paxlovid is not a substitute for vaccination.


Paxlovid may cause side effects such as impaired sense of taste, diarrhea, high blood pressure, and muscle pain. The US Food and Drug Administration has warned that using Paxlovid at the same time with some other medications may lead to possible drug interactions.


Ritonavir cannot be taken simultaneously with high blood pressure medicine and many other medicines.


According to Pfizer, clinical trials have shown that Paxlovid can reduce the risk of hospitalization and death by 88% in patients who took the drug within five days of onset of symptoms compared to those who took a placebo.


The United States gives full approval for the use of the Moderna vaccine to combat Corona

Tags

Post a Comment

0 Comments
* Please Don't Spam Here. All the Comments are Reviewed by Admin.